论文部分内容阅读
目的探讨CHOP方案治疗血管免疫母T细胞淋巴瘤的临床疗效和不良反应。方法入组18例经病理确诊的血管免疫母T细胞淋巴瘤患者,均接受CHOP方案化疗。结果全部18例患者中,10例CR(55.6%),1例PR(5.6%),7例PD(38.9%)。治疗期间大部分患者出现Ⅲ、Ⅳ度骨髓抑制,经对症处理恢复正常,未影响下一步治疗。中位随访时间48个月,全组2 a无进展生存率38.9%,其中IPI≤1分者71.4%,IPI≥2分者18.1%。结论 CHOP方案治疗血管免疫母T细胞淋巴瘤有一定疗效,特别是对IPI≤1分者疗效显著,但对IPI≥2分者效果不理想,需进一步探讨有效治疗方案。
Objective To investigate the clinical efficacy and adverse reactions of CHOP regimen in the treatment of vascular immunocompromised T-cell lymphoma. Methods 18 cases of pathologically confirmed VIMC patients received CHOP regimen. Results Of the 18 patients, 10 had CR (55.6%), 1 had PR (5.6%), and 7 had PD (38.9%). During the treatment, most patients had Ⅲ, Ⅳ degree myelosuppression, returned to normal after symptomatic treatment, did not affect the next step of treatment. The median follow-up time was 48 months. The progression-free survival rate was 38.9% in 2 years in all groups, of which 71.4% had IPI≤1 and 18.1% had IPI≥2. Conclusions The CHOP regimen is effective in treating T-cell lymphoma, especially for patients with IPI≤1. However, the effect of CHOP regimen is not satisfactory for patients with IPI≥2, so effective treatment should be further explored.